20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that members of its management team participated in BIO Asia-Taiwan July 15-19 and held strategic meetings in Taipei, Tokyo, and Seoul with companies, investors, laboratories, preventative health-check providers, and potential commercial partners as part of the Company’s East Asia roll-up strategy.

The Company is evaluating merger, acquisition, licensing, joint venture, and commercial partnership opportunities with East Asian companies whose products, customer relationships, data assets, laboratory infrastructure, or technology platforms may complement 20/20 BioLabs’ mission of advancing early detection and prevention of cancers and chronic diseases.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.